PHP
ACAD icon

Parkman Healthcare Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Parkman Healthcare Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-115,777
Closed -$2.41M – 90
2023
Q3 		$2.41M Buy
115,777
+15,777
+16% +$429K 0.44% 66
2023
Q2 		$2.4M Buy
+100,000
New +$2.22M 0.42% 68

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Parkman Healthcare Partners's ACAD Position: Q4 2023 in Review

Parkman Healthcare Partners sold out of Acadia Pharmaceuticals (ACAD) in Q4 2023, closing a stake of 115,777 shares — an estimated $2.41M sold.

Parkman Healthcare Partners first reported a position in ACAD in Q2 2023 and held it in 2 quarters. The position peaked at $2.41M in Q3 2023. 275 funds tracked by Wall St. Rank hold ACAD as of Q4 2023.

  • Parkman Healthcare Partners reported no remaining Acadia Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 115,777 Acadia Pharmaceuticals shares in Q4 2023, an estimated $2.41M.
  • Parkman Healthcare Partners first reported a position in Acadia Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Parkman Healthcare Partners's Acadia Pharmaceuticals position peaked at $2.41M in Q3 2023.
  • 275 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2023.

Based on Parkman Healthcare Partners's 13F filing for Q4 2023, filed 14 Feb 2024.